Supplements

Multiple Myeloma: A New Treatment Option for Newly Diagnosed, Transplant-Ineligible Patients

Publish date: November 4, 2019
This supplement is sponsored by Janssen Biotech, Inc.

 

Saad Z. Usmani, MD, FACP, discusses a new treatment option for newly diagnosed, transplant-ineligible patients with multiple myeloma.

Article includes:

  • An important option for patients with multiple myeloma
  • Details on the phase 3 trial
  • Efficacy and safety profile

 

 

 

Recommended Reading

Combo could be new standard for transplant-eligible, newly diagnosed myeloma patients
MDedge Hematology and Oncology
Oral triplet shows promise for relapsed/refractory myeloma
MDedge Hematology and Oncology
Quadruplet prolongs progression-free survival in newly diagnosed myeloma
MDedge Hematology and Oncology
Subcutaneous and IV daratumumab combos appear comparable in myeloma
MDedge Hematology and Oncology
Daratumumab approved in combo with VTd for transplant-eligible multiple myeloma
MDedge Hematology and Oncology
Second-generation anti-BCMA CAR T-cell therapy shows promise in myeloma trial
MDedge Hematology and Oncology
Study finds no standard for treatment discontinuation in myeloma
MDedge Hematology and Oncology
What is the optimal duration of maintenance in myeloma?
MDedge Hematology and Oncology
SEER analysis reveals medication adherence factors in newly diagnosed myeloma
MDedge Hematology and Oncology
Levofloxacin prophylaxis improves survival in newly diagnosed myeloma
MDedge Hematology and Oncology